FARMINGTON, Conn., July 10, 2012 /PRNewswire-iReach/ -- More companies are investing in kinase inhibitor research to address issues such as resistance, selectivity versus safety, developing lead compounds, and integrating chemistry and biology into development, as well as utilizing the latest technologies and techniques such as fragment- and structure-based design to develop new products. Having accurate market data and analysis is essential to companies that wish to compete on the global stage. With premium market research from the world's leading publishers, Global Information Inc. helps businesses stay on the cutting edge with the best forecasts, research, and analyses.
Global Information is pleased to announce the immediate availability of three significant new reports on Kinase Inhibitors.
Kinase Inhibitors: Global Markets -- Focus on Europe
Kinase Inhibitors: Global Markets -- Focus on US
Kinase Inhibitors: Global Markets -- Focus on Emerging Markets
The overall goal of this series is to provide a comprehensive understanding of the current and future characteristics for kinase inhibitors, which include tyrosine inhibitors, multi-target kinase inhibitors, serine/threonine inhibitors and monoclonal antibody kinase inhibitors.
Each report offers market sizes with sales and revenues figures from 2011 to 2016 for kinase inhibitors in the pharmaceutical and biotechnology industry. Market projections, market shares and a technology SWOT analysis are also included.
Global revenues for kinase inhibitors were nearly $29.1 billion in 2011 and are projected to reach nearly $40.3 billion in 2015 at a five-year compound annual growth rate (CAGR) of 6.7%. The kinase inhibitors market is witnessing an increasing number of novel kinase inhibitors being utilized in human trials, particularly in the development of next-generation inhibitors that target cancers and other disease, including inflammation.
The United States kinase inhibitor market accounted for $10.4 billion in 2011 and is expected to reach $11.6 billion by 2016 at a CAGR of 2.2%. Monoclonal antibody kinase inhibitors in the U.S. market brought in $7.6 billion in 2010 and came down to $6.6 billion in 2011. This segment is expected to continue on a downward trend at a CAGR of -4% to reach $5.4 billion in 2016.
Strong growth is expected in the emerging markets segment for kinase inhibitors, which reached $2.9 billion in 2010 and $4.1 billion in 2011 and is expected to post $8.4 billion by 2016 at a CAGR of 15.2%. Antibody kinase inhibitors in the emerging markets segment is expected to reach $4.3 billion by 2016.
An Executive Summary of this analysis and a free sample of each report is available from Global Information, Inc:
BCC Research provides a multitude of studies on the Biotechnology markets. Topics range from stem cells to enzyme inhibitors and drug discovery technologies. Each report analyzes the market along with its applications, regulatory environment, technology, market projections and market share. Discover more at http://www.giiresearch.com/publisher/BC/biotechnology.shtml
About Global Information Inc. Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.
Media Contact: Jeremy Palaia Global Information, Inc., 1-860-674-8796, Press@gii.co.jp
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
|SOURCE Global Information, Inc.|
Copyright©2012 PR Newswire.
All rights reserved